NASDAQ:PHVS

Pharvaris B.V. Stock Insider Trading

NASDAQ Stock Exchange > Healthcare > Biotechnology

Open Broker Account

$24.59

+1.14 (+4.86%)

At Close: Apr 30, 2024

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

Sorry! Image not available at this moment

About Pharvaris B.V.

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist that is in Phase II clinical trial for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks and is under Phase 2 clinical ... PHVS Profile

Golden Star

Ticker	Date	Change	Price
DHT	Apr 24	1.95%	$11.28
MLI	Apr 19	11.07%	$52.28
LPLA	Apr 19	4.31%	$262.59
DOOR	Apr 18	0.90%	$131.39
PFLT	Apr 18	1.78%	$11.25
LNG	Apr 17	3.12%	$156.81
FCN	Apr 16	2.83%	$207.62
ELV	Apr 16	5.33%	$506.97
AKR	Apr 05	6.47%	$16.53
ITCI	Apr 05	5.64%	$68.44

Unlock

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by

Sign In

Pharvaris B.V. Stock Insider Trading

About Pharvaris B.V.

Golden Star

Top Fintech Company